



ASX ANNOUNCEMENT

Vitura enters distribution agreement with MedReleaf Australia

17 MARCH 2026

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and Company**) is pleased to announce that it has entered into a binding commercial distribution agreement with **MedReleaf Australia (MedReleaf)**.

MedReleaf, a wholly owned subsidiary of Canadian-based Aurora Cannabis (NASDAQ: ACB), is one of the top 5 product suppliers by volume in the Australian market, offering a wide range of pharmaceutical-grade medicinal cannabis products under the MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant brands.

The distribution agreement enables MedReleaf's full portfolio of products to be available for the first time on Vitura's Canview platform, and be distributed through Burleigh Heads Cannabis' nationwide network. More than four in five of all Australian pharmacies actively dispensing medicinal cannabis are registered on the platform, representing around 4,700 pharmacies.

Based on current market conditions and management estimates, Vitura believes the agreement has the potential, over time, to contribute up to approximately AUD\$15 million in additional annual revenue across the Company's distribution channels. This estimate is not a forecast or guarantee and is subject to a range of factors, including patient demand, product uptake, regulatory settings and competitive dynamics. There are no minimum purchase commitments under the agreement. If achieved, this level of activity would position MedReleaf among the larger suppliers distributed by the Company.

Key terms of the distribution agreement include:

- A binding commercial distribution agreement;
- MedReleaf's medicinal cannabis product portfolio in Australia;
- Distribution via Canview and Burleigh Heads Cannabis;
- No minimum purchase or volume commitments; and
- Revenue outcomes subject to demand, regulatory and market conditions.

Vitura has expanded its Specialty Clinics Division over the past 18 months with the formation of the Company's Joint Venture with Flora Holdings (Flora) which acquired the assets of the Releaf Group in November 2024. Progress continues toward re-engagement of the 30,000 strong patient base across five physical clinic and dispensary locations in Victoria, New South Wales, and Queensland.

Releaf is now in a strong position to capitalise on the evolving regulatory landscape including telehealth and DVA requirements.

In February 2025, the Company also announced the acquisition of Candor Medical, an online telehealth clinic providing access to an additional 15,000 active patients, and more recently confirmed its integration with Vitura’s legacy brands, Cannadoc and CDA Clinics.

Vitura’s Chief Revenue Officer, Ryan Tattle, said: “This strategic partnership with MedReleaf will deliver clear commercial outcomes for both parties, including the introduction of new products and formats over time.”

“As the supplier and distribution landscape in Australia continues to rearrange and consolidate, Vitura is well positioned and excited to become a key distribution and sales partner for the MedReleaf business in Australia, as well as increase further access for pharmacy customers and their patients,” Mr Tattle said.

“In an evolving and competitive market, Vitura has experienced strong revenue growth across all businesses over the last five years, growing from \$21.7m in FY21 to \$124m last financial year. The Company expects this strong growth to continue and the new distribution agreement with MedReleaf will certainly add to that,” he said.

**** ENDS ****

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company’s relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient’s details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

- www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- www.candor.com.au

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

- www.releaf.com.au

The Company owns a 50% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

- www.cdaclinics.com.au

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

- www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

Authorised by

Authorised for release to the ASX by the Board of Vitura Health Limited.

Contact

Vitura Health Limited

Ryan Tattle
Chief Revenue Officer
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.